SCHEMBL5171111

SCHEMBL5171111

CS(=O)(=O)c1ccccc1-c1cccc(C(N)=O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 2/20 0.50
BAZ2A Q9UIF9 2/20 0.50
PDE4A P27815 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
F10 P00742 5/20 0.47
F2 P00734 3/20 0.47
PARP1 P09874 2/20 0.45
BRD9 Q9H8M2 1/20 0.45
PRSS1 P07477 2/20 0.45
PRSS2 P07478 2/20 0.45
PRSS3 P35030 2/20 0.45
RAB9A P51151 2/20 0.44
PDK2 Q15119 1/20 0.44
NPC1 O15118 1/20 0.44
KMT2A Q03164 1/20 0.43
PRKCI P41743 1/20 0.43
BRD4 O60885 2/20 0.43
CREBBP Q92793 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29718823 0.86 F10 (0.57) BAZ2BBAZ2AF10F2PRSS1
SCHEMBL9392177 0.85 SLC9A1 (0.52) F10F2
Hydrochloric Acid SCHEMBL7826712 0.84 SLC9A1 (0.51)
SCHEMBL6303170 0.83 MKNK1 (0.54) BAZ2BBAZ2AF10F2PARP1
SCHEMBL7824603 0.82 CA12 (0.53) RAB9APDK2NPC1
Hydrochloric Acid SCHEMBL8700277 0.82 F10 (0.51) F10F2PRSS1PRSS2PRSS3
SCHEMBL16618470 0.80 PTGS2 (0.47) KMT2A
SCHEMBL5307077 0.79 PARP1 (0.56) BAZ2BBAZ2APARP1PRSS1PRSS2
SCHEMBL29718677 0.78 BAZ2B (0.42) BAZ2BBAZ2APDE4APDE4BPDE4C
SCHEMBL18234332 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220135536-A1 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH BAYER AKTIENGESELLSCHAFT (DE) 2022-05-05 US disclosed
EP-1773774-A2 HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS Merck & Co., Inc. (US) 2007-04-18 EP disclosed
EP-1773792-A1 INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS Merck & Co., Inc. (US) 2007-04-18 EP disclosed
WO-2006014918-A2 HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK & CO., INC. (US) 2006-02-09 WO disclosed
WO-2006015158-A1 INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK & CO., INC. (US) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135536-A1 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH DHODH, DHPS, DPYD BAZ2B 1802/4885BAZ2A 2349/4885PDE4A 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.